Acotec Scientific Holdings Ltd. Secures Approval from PRC National Medical Products Administration for Armoni-HP® Peripheral High-Pressure Balloon Dilation Catheter

Reuters
06/25
Acotec Scientific Holdings Ltd. Secures Approval from PRC National Medical Products Administration for Armoni-HP® Peripheral High-Pressure Balloon Dilation Catheter

Acotec Scientific Holdings Limited has announced that it has received regulatory approval from the PRC National Medical Products Administration for its Peripheral High-pressure Balloon Dilation Catheter, Armoni-HP®. This device is intended for use in percutaneous transluminal angioplasty in peripheral blood vessels, including femoral, iliac, and renal vessels, and for treating stenosis in arteriovenous fistulas used for dialysis. The Armoni-HP® features a non-compliant balloon catheter with an ultra-high-strength fiber-composite design, offering reliable clinical performance with a working pressure of up to 40 atm. Acotec plans to initiate marketing activities in the PRC market at an appropriate time. Shareholders and potential investors are advised to exercise due care when dealing with the company's shares.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Acotec Scientific Holdings Ltd. published the original content used to generate this news brief on June 25, 2025, and is solely responsible for the information contained therein.

免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。

熱議股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10